Can vitamin a make a failed myeloma drug effective again?
NCT ID NCT06536413
First seen Apr 06, 2026
Summary
This study tests whether adding a vitamin A derivative (ATRA) to a standard drug combination (carfilzomib and dexamethasone) can overcome resistance in multiple myeloma patients whose cancer no longer responds to carfilzomib. About 42 adults with relapsed/refractory myeloma will receive ATRA alongside their carfilzomib-based therapy. The goal is to see if the combination is safe and can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
All-Trans Retinoic Acid (ATRA) combined with carfilzomib and dexamethasone
What this could lead to
If it works, this could offer a new treatment option for multiple myeloma patients whose cancer has become resistant to carfilzomib, potentially extending remission.
What could go wrong
This is an early-phase trial with only 42 participants, so results may not apply broadly. ATRA may not restore sensitivity in all patients, and side effects from the combination are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.